Cost-Effectiveness of Vibrant System vs. Linaclotide in Chronic Idiopathic Constipation
On the basis of lower costs and improved QALYs, the Vibrant System should be considered a first-line therapy for CIC and should be covered by insurers.
Authors
- Jeffrey Voigt (ORCID: https://orcid.org/0000-0002-1755-8612)
- Christine L. Frissora (ORCID: https://orcid.org/0000-0003-1742-4769)
Institutions
- Cornell University (US)
- Ridgewood Public Schools (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1007/s12325-024-03035-0
- Citations
- 2
- Primary Topic
- Gastrointestinal motility and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.93